Scarica l'app Stockscreener
108.62
1.06%
1.14
Dopo l'orario di chiusura:
104.04
-4.58
-4.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$107.48
Aprire:
$107.77
Volume 24 ore:
648.65K
Relative Volume:
0.89
Capitalizzazione di mercato:
$6.50B
Reddito:
$379.25M
Utile/perdita netta:
$-77.34M
Rapporto P/E:
-67.37
EPS:
-1.6122
Flusso di cassa netto:
$-27.87M
1 W Prestazione:
+3.35%
1M Prestazione:
+15.20%
6M Prestazione:
+51.26%
1 anno Prestazione:
+117.54%
Intervallo 1D:
$106.43
$109.05
Intervallo di 1 settimana:
$102.50
$109.28
Portata 52W:
$36.88
$109.28
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
108.62 | 6.44B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-09-24 | Iniziato | TD Cowen | Buy |
| 2025-08-11 | Ripresa | Stifel | Buy |
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Mirum Pharmaceuticals Reports Strong Q4 2025 Earnings and 2026 Guidance - Intellectia AI
Mirum Pharmaceuticals Files For Offering Of Up To 8.96 Million Shares Of Common Stock By The Selling Stockholders - TradingView
Mirum (MIRM) Q4 2025 Earnings Call Transcript - aol.com
Earnings call transcript: Mirum Pharmaceuticals’ Q4 2025 revenue exceeds expectations - Investing.com India
Mirum Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Mirum Pharmaceuticals earnings up next as pipeline readouts loom - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Powerhouse with 9.63% Potential Upside - DirectorsTalk Interviews
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), Mirum Pharmaceuticals, Inc. has officially registered a public offering plan of common stock initiated by selling shareholders. - Bitget
Is It Too Late To Consider Mirum Pharmaceuticals (MIRM) After Its 115% One-Year Surge? - Yahoo Finance
Insights Ahead: Mirum Pharmaceuticals's Quarterly Earnings - Benzinga
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - bdtonline.com
Will Mirum Pharmaceuticals Inc. stock hit new highs in YEARJuly 2025 Snapshot & Weekly High Return Stock Forecasts - mfd.ru
Mirum Pharmaceuticals (NASDAQ:MIRM) Research Coverage Started at Royal Bank Of Canada - Defense World
Portfolio Recap: Will Mirum Pharmaceuticals Inc stock hit new highs in YEARJuly 2025 Review & Risk Controlled Daily Plans - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Raised to "Moderate Buy" at Royal Bank Of Canada - MarketBeat
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD By Investing.com - Investing.com Canada
Earnings Recap: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 Trends & Free Community Consensus Stock Picks - baoquankhu1.vn
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 - Bluefield Daily Telegraph
Drugmaker Mirum sets Feb. 25 call on 2025 results - Stock Titan
RBC Capital Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Outperform Recommendation - Nasdaq
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week HighTime to Buy? - MarketBeat
Mirum Can Sustain Revenue Growth with Multiple Catalysts, RBC Says - marketscreener.com
Mirum Pharmaceuticals stock reaches all-time high at 106.27 USD - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance
Mirum Pharmaceuticals (MIRM) Expected to Announce Earnings on Wednesday - MarketBeat
Saira Ramasastry, Mirum director, sells $204k in shares By Investing.com - Investing.com Canada
Saira Ramasastry, Mirum director, sells $204k in shares - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A Biotech Gem with 11.25% Upside Potential - DirectorsTalk Interviews
TimesSquare Capital Management LLC Makes New $22.04 Million Investment in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Is Mirum Pharmaceuticals Inc. a turnaround storyDollar Strength & Real-Time Stock Price Movement Reports - mfd.ru
Why Mirum Pharmaceuticals Inc. stock is trending among retail traders - mfd.ru
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy - ChartMill
What are analysts’ price targets for Mirum Pharmaceuticals Inc.Earnings Summary Report & Weekly Sector Rotation Insights - mfd.ru
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will Mirum Pharmaceuticals Inc. benefit from AI trendsShare Buyback & Expert Verified Stock Movement Alerts - mfd.ru
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MEXC
Mirum Pharmaceuticals Grants Stock Awards to New Employees - Intellectia AI
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup - ChartMill
Candriam S.C.A. Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals expands portfolio in rare disease drug focus - Traders Union
Gap Down: Can Mirum Pharmaceuticals Inc benefit from deglobalizationJuly 2025 PreEarnings & Fast Entry Momentum Alerts - baoquankhu1.vn
Health Canada approves Livmarli for PFIC and ALGS - The Pharma Letter
Mirum Pharmaceuticals, Inc. $MIRM Shares Purchased by Penserra Capital Management LLC - MarketBeat
Sentiment Review: Is Mirum Pharmaceuticals Inc a turnaround storyFed Meeting & Safe Entry Trade Signal Reports - baoquankhu1.vn
Health Canada LIVMARLI Decision And Bluejay Deal Shape Mirum Outlook - Yahoo Finance
Mirum Pharmaceuticals says Health Canada authorizes Livmarli for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients - marketscreener.com
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - BioSpace
Mirum Pharmaceuticals Stumbles on Health Canada Approval - Baystreet.ca
Mirum Pharmaceuticals' Tablet Formulation of its Cholestasic Pruritus Treatment Livmarli Approved in Canada - marketscreener.com
for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Business Wire
Is Mirum Pharmaceuticals on a Strong Path to Profitability? - AOL.com
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.52%
1.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):